Checkpoint inhibitor therapies can be thought of as the molecular "brake release" for the immune system. These drugs eliminate the protein barriers that impede the immune system from recognizing and targeting cancer cells ...
Jun 20, 2024
0
42
Researchers at the National Institutes of Health (NIH) have developed a non-chemotherapy treatment regimen that is achieving full remissions for some people with aggressive B-cell lymphoma that has come back or is no longer ...
Jun 19, 2024
0
35
Glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) is superior to rituximab (R)-GemOx for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), according to a study presented at the annual hybrid congress ...
Jun 26, 2024
0
0
Penn Medicine's patients of color are far less likely than white patients to receive a novel gene therapy pioneered there and hailed as a cure for some blood cancers, new research shows.
Jun 11, 2024
0
0
While CAR T cell therapy has revolutionized treatment for many blood cancers, including non-Hodgkin lymphoma (NHL), many patients who receive CAR T cell therapy do not experience a long-term remission. For those whose cancers ...
Jun 1, 2024
0
2
